Qualitätskontrolle in der Molekularpathologie

Literatur

• 1 Atkinson A J, Colburn W A, DeGruttolz V G. et al. Biomarkers Definitions Working Group . Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.  Clin Pharmacol Ther. 2001;  69 89-95
• 2 Amado R G, Wolf M, Peeters M. et al . Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.  J Clin Oncol. 2008;  26 1626-1634
• 3 Bokemeyer C, Bondarenko I, Makhson A. et al . Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.  J Clin Oncol. 2009;  27 663-671
• 4 Van Cutsem E, Kohne C H, Hitre E. et al . Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.  N Engl J Med. 2009;  360 1408-1417
• 5 Mok T S, Wu Y L, Thongprasert S. et al . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.  N Engl J Med. 2009;  361 947-957